Ionis Pharmaceuticals (IONS) executive Devers sold 8,353 shares for $634K at $75.95
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Shannon L. Devers (EVP, Chief Human Resources Ofc at Ionis Pharmaceuticals Inc., IONS) reported that they sold 8,353 shares for $634K at $75.95, and acquired 17,377 shares between Jan 15, 2026 and Jan 16, 2026. After these transactions the filing shows 26,518 shares held directly.
- Reporting person
- Devers Shannon L.
- Role
- EVP, Chief Human Resources Ofc
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +17,377 | - | - | 34,871 direct |
| Jan 16, 2026 | Open-market sale (S) | Common Stock2, 3 | -8,353 | $75.95 | $634K | 26,518 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | Grant or award (A) | Performance Restricted Stock UnitsOn 25,800 Common Stock4, 5 | +25,800 | - | - | 47,800 direct |
| Jan 15, 2026 | Exercise or conversion of a derivative (M) | Restricted Stock UnitOn 17,377 Common Stock6, 7 | -17,377 | - | - | 43,029 direct |
| Jan 15, 2026 | Grant or award (A) | Restricted Stock UnitOn 9,675 Common Stock6, 7, 8 | +9,675 | - | - | 52,704 direct |
Holdings before and after
- Common Stock: 17,494 to 26,518 direct
- Performance Restricted Stock Units: 22,000 to 47,800 direct
- Restricted Stock Unit: 60,406 to 52,704 direct
Footnotes from the filing
- 1. Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
- 2. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.94 to $75.96 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- 4. Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
- 5. The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
- 6. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- 7. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
- 8. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Devers report in this IONS Form 4?
Shannon L. Devers (EVP, Chief Human Resources Ofc at Ionis Pharmaceuticals Inc., IONS) reported that they sold 8,353 shares for $634K at $75.95, and acquired 17,377 shares between Jan 15, 2026 and Jan 16, 2026. After these transactions the filing shows 26,518 shares held directly.
How many IONS shares does Devers hold after this filing?
The filing shows 26,518 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this IONS insider sale made under a 10b5-1 plan?
The filing's footnotes do not mention a Rule 10b5-1 trading plan.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for IONS
Across the 14 sessions after earlier IONS headlines, the stock closed higher 6 times and lower 7 times, with a median move of 2.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IONS | SPY |
|---|---|---|---|
| Jan 12, 2026 | Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts | +1.7% | +0.2% |
| Jan 7, 2026 | Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B | +2.1% | -0.3% |
| Jan 6, 2026 | Ionis to present at 44th Annual J.P. Morgan Healthcare Conference | +3.8% | +0.6% |
| Dec 2, 2025 | Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) | -0.8% | +0.2% |
| Dec 1, 2025 | Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG) | -0.9% | -0.5% |
| Nov 14, 2025 | DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) | +2.4% | -0.0% |
Earlier insider filings at IONS
- Jan 21, 2026EVP, Corp and Development Ops Birchler Brian sold $636,933 worth of shares (8,480 units at $75.11) and converted options into 20,089 shares, increasing direct ownership by 24% to 60,435 units (SEC Form 4)
- Jan 21, 2026EVP, Chief Scientific Officer Bennett C Frank converted options into 21,055 shares and sold $674,622 worth of shares (8,977 units at $75.15), increasing direct ownership by 15% to 94,757 units (SEC Form 4)
- Jan 21, 2026EVP, Chief Business Officer Baroldi Joseph converted options into 19,887 shares and sold $610,276 worth of shares (8,056 units at $75.75), increasing direct ownership by 33% to 40,431 units (SEC Form 4)
- Jan 9, 2026EVP, Chief Human Resources Ofc Devers Shannon L. exercised 44,199 shares at a strike of $51.25 and sold $3,760,577 worth of shares (44,199 units at $85.08) (SEC Form 4)
- Jan 6, 2026SEC Form 4 filed by EVP, Chf GL Pdt Str Ofcr Jenne Kyle
Keep researching IONS
- IONS insider tradesEvery buy and sale reported by Ionis Pharmaceuticals Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- IONS earnings historyPast Ionis Pharmaceuticals Inc. earnings releases, newest first.
- IONS financial statementsRevenue, profit, cash flow and balance sheet from Ionis Pharmaceuticals Inc.'s SEC filings.
Quantisnow market dataNASDAQ
IONS
Ionis Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for IONS
Full IONS profile on Quantisnow Follow IONS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time